Fibrogen, Inc Announces Resignation of Kurkijärvi as Director, Effect from June 30, 2021
April 13, 2021 at 04:23 pm EDT
Share
On April 9, 2021, Kalevi Kurkij rvi, Ph.D., provided notification of his resignation from the Board of Directors of FibroGen, Inc. effective June 30, 2021. Dr. Kurkij rvi's resignation as a director is not the result of any disagreement with FibroGen on any matter relating to FibroGen's operations, policies or practices. Dr. Kurkij rvi joined FibroGen's Board in November 1996 and served in a number of capacities during his tenure, including as a member of the Audit Committee as well as on the board of directors of company subsidiary, FibroGen Europe Oy, since 1997, and most recently as its Managing Director since 2019.
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
FIBROGEN, INC. 
